C S Fuchs1, S Azevedo2, T Okusaka3, J-L Van Laethem4, L R Lipton5, H Riess6, C Szczylik7, M J Moore8, M Peeters9, G Bodoky10, M Ikeda11, B Melichar12, R Nemecek13, S Ohkawa14, A Świeboda-Sadlej15, S A Tjulandin16, E Van Cutsem17, R Loberg18, V Haddad19, J L Gansert20, B A Bach21, A Carrato22. 1. Department of Medical Oncology/Solid Tumor Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: charles_fuchs@dfci.harvard.edu. 2. Oncology Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. 3. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. 4. Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium. 5. Medical Oncology, Royal Melbourne Hospital, Parkville, VIC, Australia. 6. Department of Hematology, Oncology, and Tumor Immunology, Charité University, Berlin, Germany. 7. Department of Oncology, Military Institute of Health Services, Warsaw, Poland. 8. Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. 9. Department of Oncology, Antwerp University Hospital, Edegum, Belgium. 10. Department of Oncology, St László Hospital, Budapest, Hungary. 11. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 12. Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc. 13. Department of Oncology, Masaryk University Medical School and Masaryk Memorial Cancer Institute, Brno, Czech Republic. 14. Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. 15. Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. 16. Department of Clinical Pharmacology and Chemotherapy, Russian Cancer Research Center, Moscow, Russia. 17. Digestive Oncology, University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium. 18. Medical Sciences, Amgen Inc., Thousand Oaks, USA. 19. Global Biostatistical Science, Amgen Ltd, Cambridge, UK. 20. Global Development, Thousand Oaks. 21. Development Oncology Therapeutics, Amgen Inc., Thousand Oaks, USA. 22. Medical Oncology Department, University Hospital Ramon y Cajal, Madrid, Spain.
Abstract
BACKGROUND: This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated metastatic pancreatic adenocarcinoma were randomly assigned 2 : 2 : 1 to receive intravenous gemcitabine 1000 mg/m(2) (days 1, 8, and 15 of each 28-day cycle) plus placebo, ganitumab 12 mg/kg, or ganitumab 20 mg/kg (days 1 and 15 of each cycle). The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), safety, and efficacy by levels of circulating biomarkers. RESULTS: Overall, 322 patients were randomly assigned to placebo, 318 to ganitumab 12 mg/kg, and 160 to ganitumab 20 mg/kg. The study was stopped based on results from a preplanned futility analysis; the final results are reported. Median OS was 7.2 months [95% confidence interval (CI), 6.3-8.2] in the placebo arm, 7.0 months (95% CI, 6.2-8.5) in the ganitumab 12-mg/kg arm [hazard ratio (HR), 1.00; 95% CI, 0.82-1.21; P = 0.494], and 7.1 months (95% CI, 6.4-8.5) in the ganitumab 20-mg/kg arm (HR, 0.97; 95% CI, 0.76-1.23; P = 0.397). Median PFS was 3.7, 3.6 (HR, 1.00; 95% CI, 0.84-1.20; P = 0.520), and 3.7 months (HR, 0.97; 95% CI, 0.77-1.22; P = 0.403), respectively. No unexpected toxicity was observed with ganitumab plus gemcitabine. The circulating biomarkers assessed [insulin-like growth factor-1 (IGF-1), IGF-binding protein-2, and -3] were not associated with a treatment effect on OS or PFS by ganitumab. CONCLUSION:Ganitumab combined with gemcitabine had manageable toxicity but did not improve OS, compared with gemcitabine alone in unselected patients with metastatic pancreatic cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01231347.
RCT Entities:
BACKGROUND: This double-blind, phase 3 study assessed the efficacy and safety of ganitumab combined with gemcitabine as first-line treatment of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated metastatic pancreatic adenocarcinoma were randomly assigned 2 : 2 : 1 to receive intravenous gemcitabine 1000 mg/m(2) (days 1, 8, and 15 of each 28-day cycle) plus placebo, ganitumab 12 mg/kg, or ganitumab 20 mg/kg (days 1 and 15 of each cycle). The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), safety, and efficacy by levels of circulating biomarkers. RESULTS: Overall, 322 patients were randomly assigned to placebo, 318 to ganitumab 12 mg/kg, and 160 to ganitumab 20 mg/kg. The study was stopped based on results from a preplanned futility analysis; the final results are reported. Median OS was 7.2 months [95% confidence interval (CI), 6.3-8.2] in the placebo arm, 7.0 months (95% CI, 6.2-8.5) in the ganitumab 12-mg/kg arm [hazard ratio (HR), 1.00; 95% CI, 0.82-1.21; P = 0.494], and 7.1 months (95% CI, 6.4-8.5) in the ganitumab 20-mg/kg arm (HR, 0.97; 95% CI, 0.76-1.23; P = 0.397). Median PFS was 3.7, 3.6 (HR, 1.00; 95% CI, 0.84-1.20; P = 0.520), and 3.7 months (HR, 0.97; 95% CI, 0.77-1.22; P = 0.403), respectively. No unexpected toxicity was observed with ganitumab plus gemcitabine. The circulating biomarkers assessed [insulin-like growth factor-1 (IGF-1), IGF-binding protein-2, and -3] were not associated with a treatment effect on OS or PFS by ganitumab. CONCLUSION:Ganitumab combined with gemcitabine had manageable toxicity but did not improve OS, compared with gemcitabine alone in unselected patients with metastatic pancreatic cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01231347.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Diether Lambrechts; Bart Claes; Paul Delmar; Joke Reumers; Massimiliano Mazzone; Betül T Yesilyurt; Roland Devlieger; Chris Verslype; Sabine Tejpar; Hans Wildiers; Sanne de Haas; Peter Carmeliet; Stefan J Scherer; Eric Van Cutsem Journal: Lancet Oncol Date: 2012-05-17 Impact factor: 41.316
Authors: Anthony W Tolcher; John Sarantopoulos; Amita Patnaik; Kyriakos Papadopoulos; Chia-Chi Lin; Jordi Rodon; Barbara Murphy; Bruce Roth; Ian McCaffery; Kevin S Gorski; Brianne Kaiser; Min Zhu; Hongjie Deng; Greg Friberg; Igor Puzanov Journal: J Clin Oncol Date: 2009-09-28 Impact factor: 44.544
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Christoforos Kosmidis; Konstantinos Sapalidis; Efstathios Kotidis; Nikolaos Mixalopoulos; Paul Zarogoulidis; Drosos Tsavlis; Sofia Baka; Yan-Gao Man; John Kanellos Journal: Ann Transl Med Date: 2016-05
Authors: Joanne W Chiu; Hilda Wong; Roland Leung; Roberta Pang; Tan-To Cheung; Sheung-Tat Fan; Ronnie Poon; Thomas Yau Journal: Oncologist Date: 2014-08-12
Authors: Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254